Meeting
2020 ASCO Virtual Scientific Program
Phase II study of durvalumab plus total neoadjuvant therapy (TNT) in locally advanced rectal cancer: The GEMCAD-1703 DUREC trial.
Authors
Jaume Capdevila
Medical Oncology Department, Vall d’Hebron University Hospital; Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Jaume Capdevila , Ismael Macias Declara , Maria Carmen Riesco Martinez , Joan Maurel , Jorge Hernando , Vicente Alonso , Begoña Graña Suárez , Javier Gallego Plazas , Ferran Losa , Ruth Vera , Marcos Melian , Begona Navalpotro , Daniel Acosta , Marc Diez , Alejandro Garcia-Alvarez , Xabier Garcia-Albeniz , Carlos Fernandez-Martos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
2018-004835-56
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4122)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4122
Abstract #
TPS4122
Poster Bd #
114
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.
First Author: Jesse Joshua Smith
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe
Poster
2022 ASCO Annual Meeting
Preoperative chemoradiotherapy with capecitabine with or without temozolomide in patients with locally advanced rectal cancer: A prospective, randomized phase 2 study stratified by MGMT (O6-methylguanine DNA methyltransferase) status: KCSG-CO17-02.
First Author: Chung Ryul Oh
Poster
2022 ASCO Annual Meeting
Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for patients with pMMR, high-risk, and locally advanced middle to low rectal cancer.
First Author: Aiwen WU